Crossmark

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action

Crossref DOI link: https://doi.org/10.1007/s11523-016-0463-4

Published Online: 2016-11-15

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Duran, I.

Lambea, J.

Maroto, P.

González-Larriba, J. L.

Flores, Luis

Granados-Principal, S.

Graupera, M.

Sáez, B.

Vivancos, A.

Casanovas, O.
Funding

Funding for this research was provided by:

Novartis Pharmaceuticals
License Information

License valid from 2016-11-15